While expressing optimism about the potential of new treatments from BMS and J&J to secure FDA approval in earlier lines of treatment for multiple myeloma, experts questioned aspects of the treatment paradigm.
While expressing optimism about the potential of new treatments from BMS and J&J to secure FDA approval in earlier lines of treatment for multiple myeloma, experts questioned aspects of the treatment paradigm.